VistaGen Therapeutics Set to Join the Russell 2000® Index
June 16 2021 - 8:00AM
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical
company committed to developing and commercializing a new
generation of medicines with the potential to go beyond the current
standard of care for anxiety, depression and other central nervous
system (CNS) disorders, today announced the Company will be added
to the Russell 2000® Index at the conclusion of the 2021 Russell
Indexes annual reconstitution, effective after the U.S. market
opens on Monday, June 28, 2021, according to a preliminary list of
additions posted on June 4, 2021.
"Inclusion in the Russell 2000® Index, which is
one of the most cited performance benchmarks for small-cap
companies, is another important milestone for VistaGen and an
achievement we expect will increase overall awareness and exposure
of our company within the investment community,” stated Shawn K.
Singh, Chief Executive Officer of VistaGen. “Our late-stage anxiety
and depression programs have exciting potential to change lives. We
look forward to introducing our company to a wider investor
audience as we continue to execute on noteworthy milestones during
the second half of the year and beyond.”
Russell U.S. Indexes are widely used by
investment managers and institutional investors as the basis for
index funds and as benchmarks for active investment strategies.
Approximately $10.6 trillion in assets are benchmarked
against Russell U.S. Indexes. Russell U.S. Indexes are part of FTSE
Russell, a leading global index provider.
The annual Russell reconstitution captures the
4,000 largest U.S. stocks as of May 7, 2021, ranking them by total
market capitalization. Membership in the U.S. all-cap Russell 3000®
Index, which remains in place for one year, means automatic
inclusion in the large-cap Russell 1000® Index or small-cap Russell
2000® Index, as well as the appropriate growth- and value-style
indexes. FTSE Russell determines membership for its Russell Indexes
primarily by objective, market-capitalization rankings, and style
attributes.
For more information on the Russell Indexes,
please visit the “Russell Reconstitution” section on the FTSE
Russell website at www.ftserussell.com.
About VistaGenVistaGen
Therapeutics is a biopharmaceutical company committed to developing
and commercializing innovative medicines with the potential to go
beyond the current standard of care for anxiety, depression, and
other CNS disorders. Each of VistaGen's drug candidates has a
differentiated potential mechanism of action, has been
well-tolerated in all clinical studies to date and has therapeutic
potential in multiple CNS markets. For more information, please
visit www.VistaGen.com and connect with VistaGen
on Twitter, LinkedIn and Facebook.
About FTSE RussellFTSE Russell
is a global index leader that provides innovative benchmarking,
analytics and data solutions for investors worldwide. FTSE Russell
calculates thousands of indexes that measure and benchmark markets
and asset classes in more than 70 countries, covering 98% of the
investable market globally.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
Approximately $17.9 trillion is currently benchmarked to FTSE
Russell Indexes. For over 30 years, leading asset owners, asset
managers, ETF providers and investment banks have chosen FTSE
Russell Indexes to benchmark their investment performance and
create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE
Russell Index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on applying the highest
industry standards in index design and governance and embraces the
IOSCO Principles. FTSE Russell is also focused on index innovation
and customer partnerships as it seeks to enhance the breadth, depth
and reach of its offering.
FTSE Russell is wholly owned by London Stock
Exchange Group.
Forward Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the federal securities laws. These forward-looking
statements involve known and unknown risks that are difficult to
predict and include all matters that are not historical facts. In
some cases, you can identify forward-looking statements by the use
of words such as “may,” “could,” “expect,” “project,” “outlook,”
“strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “strive,” “goal,” “continue,”
“likely,” “will,” “would” and variations of these terms and similar
expressions, or the negative of these terms or similar expressions.
Such forward-looking statements are necessarily based upon
estimates and assumptions that, while considered reasonable by us
and our management, are inherently uncertain. Our actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties
relating to the trading of our securities as it relates to the FTSE
Russell Indexes annual reconstitution and the inclusion of the
Company on the Russell 2000 Index following such reconstitution,
which statements reflects the intent, belief, or current
expectations of members of our management team. These risks and
others are more fully discussed in the section entitled "Risk
Factors" in our most recent Annual Report on Form 10-K for the year
ended March 31, 2020, and in our most recent Quarterly Report on
Form 10-Q for the quarter ended December 31, 2020, as well as
discussions of potential risks, uncertainties, and other important
factors in our other filings with the U.S. Securities and Exchange
Commission (SEC). Our SEC filings are available on the SEC’s
website at www.sec.gov. You should not place undue reliance on
these forward-looking statements, which apply only as of the date
of this press release and should not be relied upon as representing
our views as of any subsequent date. We explicitly disclaim any
obligation to update any forward-looking statements, other than as
may be required by law. If we do update one or more forward-looking
statements, no inference should be made that we will make
additional updates with respect to those or other forward-looking
statements.
VistaGen Company ContactMark McPartland / Mark
FlatherVistaGen Therapeutics Phone: (650) 577-3606Email:
IR@vistagen.com
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Sep 2023 to Sep 2024